DOCKET NO: 17293DIV(HL)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Massaro et al Serial No.: 09/919,195 Conf. No. 4830 July 31, 2001 Filed:

For: METHODS AND COMPOSITIONS FOR THE

TREATMENT AND PREVENTION OF LUNG DISEASE

Examiner: Seaman, Margaret

Washington, D.C. 20231

Assistant Commissioner for Patents

Group Art Unit: 1625

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express mail (Label No. EL897855846US) in an envelope addressed to: Box Amendment-Fee; Assistant Commissioner

Washington, D.C. 20231 on:

Date of Deposit

Person making Deposit:

Date of Signature:

REPLY AND AMENDMENT

AUG 2 1 2002

Dear Sir:

TECH CENTER 1600/2900

This Reply is being filed in reply to the Office Action mailed April 24, 2002. Applicants have the following comments.

08/20/2002 SZEWDIE1 00000093 010885 09919195

01 FC:115

110.00 CH

<u>AMENDMENT</u>

Kindly cancel pending claims 1-12 without prejudice to their later prosecution.

REMARKS

Applicants have carefully considered the Examiner's comments in the Office Action dated April 24, 2002, and respond as follows. In order to expediate allowance, claims 1-12 have 1 has been amended to indicate that the composition comprises a pharmacologically acceptable vehicle suitable for treatment of lung pathologies and a therapeutically effective amount of the RARI antagonist. Support for the amendments can be found on pages 5, 6, 7 and 12 of the specification.

Rejections Pursuant to 35 USC §102 and 35 USC §103

The Examiner has rejected claims 1-12 as rendered obvious by one or more of US Patents 5,776,699, 6,218,128, and 6,228,848, to Klein. The Applicants have cancelled these claims without